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Iron is essential to many biological and metabolic processes used in all organisms, 
but excess iron can result in complications such as cirrhosis, diabetes, and heart failure. 
Cardiac iron overload has been linked to increased oxidative stress and cell death. 
Oxidative stress has been shown to play a role in cardiovascular diseases. Antioxidants 
can counter the effect of oxidative stress by scavenging reactive oxygen species. Protein 
kinase B (Akt) promotes cell survival by regulating growth, antioxidant production, and 
cell death in cardiomyoctes. The aim of this study was to examine the cardioprotective 
role of secoisolariciresinol diglucoside (SDG), a phytochemical extracted from flax 
seeds, in an in vitro cardiac iron overload condition. H9c2 cardiac cells were incubated 
with 50 μM iron for either 6, 12 or 24 hours and/or received a SDG pretreatment of 250 
μM or 500 μM for 24 hours. Flow cytometry was used to assess necrotic cells and 
changes in the mitochondrial membrane potential. Western blot was used to determine 
the protein expression of antioxidants (manganese superoxide dismutase and catalase) 
and redox sensitive proteins, 5’AMP-activated protein kinase (AMPK), signal transducer 
and activator of transcription 3 (STAT3), Akt, and the mammalian target of rapamycin 
(mTOR). Pretreatment of SDG reduced the amount of necrotic cells (24.3%) after iron 
treatment. Pretreatment of SDG resulted in increased protein expression of catalase after 
24 hours of iron treatment, and increased activity of AMPK and STAT3 after 12 hours of 
iron treatment. Akt activity and 4-hydroxynonenal (4HNE) levels were decreased after 6 
hours of iron treatment when pretreated with SDG. This study demonstrates that SDG can 
act as an antioxidant by attenuating cell death, oxidative stress, and increasing the level of 





Faculty and students in the Department of Biology are bound together by a 
common interest in explaining the diversity of life, the fit between form and function, and 
the distribution and abundance of organisms. This research project focussed on the field 
of human sciences and investigated the mechanism behind the antioxidant activity of 
secoisolariciresinol diglucoside (SDG) in an in vitro cardiac iron overload model. The 
findings suggest SDG protects cardiomyocytes from iron overload by increasing 
antioxidant levels and pro-survival proteins. SDG may be a therapeutic option for 
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Akt - Protein Kinase B 
AMPK - Adenosine monophosphate-activated protein kinase 
Atg - Autophagy protein 
ATP - Adenosine triphosphate 
Bax - B-cell lymphoma-associated X protein 
Bcl - B-cell lymphoma 
ED - Enterodiol 
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Fe3+ - Ferric 
Fe2+ - Ferrous 
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GPx - Glutathione peroxidase 
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H2O2 - Hydrogen peroxide 
HSP - Heat shock protein  
IL - Interleukin  
˚OH – Hydroxyl radical  
LDL - Low-density lipoprotein 
mTOR - Mammalian target of rapamycin 
mtDNA - Mitochondrial DNA 
mPTP - Mitochondrial permeability transition pore 
SOD2/MnSOD - Manganese superoxide dismutase 
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MI - Myocardial infarction 
NTBI - Non-transferrin bound iron 
LTCC - L-type Ca2+ channels 
PI3K - Phosphoinositide 3-kinase 
ROS - Reactive oxygen species 
SECO - Secoisolariciresinol  
SDG - Secoisolariciresinol diglucoside  
STAT - Signal transducer and activator of transcription 
O2˚- - Superoxide anion 
SOD - Superoxide dismutase 
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1.0 Iron Overload 
 Iron is essential to biochemical, metabolic, and biological processes in all 
organisms, where it is the critical component of haemoglobin and is needed for energy 
production (1). The biological importance of iron and its toxicity is a result of rapid 
oxidation-reduction cycling between ferric (Fe3+) and ferrous (Fe2+) states at 
physiological conditions (2). Therefore, iron is precisely regulated under physiological 
conditions by several intrinsic feedback mechanisms that utilize transporters, iron-
binding proteins and receptors (2). However, an excess of iron can result in complications 
such as heart disease, cirrhosis, and diabetes (1). Iron overload occurs when the amount 
of free iron exceeds the capacity of iron binding to serum transferrin (1). This excess iron 
results in highly reactive non-transferrin-bound iron (NTBI) which can bypass the 
negative-feedback mechanisms regulating cellular iron uptake (2). Excess NTBI uptake 
combined with the lack of an effective iron excretory pathway leads to the expansion of 
the labile intracellular iron pool as well as the formation of reactive oxygen species 
(ROS) which results in lipid peroxidation and oxidative damage to proteins (2).  Excess 
iron can accumulate in the liver, spleen, heart, and central nervous system (3). Cardiac 
iron overload is caused by the accumulation of iron in the myocardium and is the leading 
cause of death in patients receiving chronic blood transfusion therapy (3). One unit of 
transfused blood contains about 250 mg of iron and over long periods of repeated blood 
transfusions iron is deposited into multiple organs leading to iron overload (3). Chronic 
cardiac iron overload can lead to a variety of arrhythmias which can lead to heart failure 
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(1). Recent studies have suggested that altered calcium homeostasis and increased 
production of ROS each play a role during cardiac iron overload (1, 2). 
1.1 Iron overload conditions 
Primary hemochromatosis is a common inherited disorder where excessive iron 
accumulation results primarily from increased gastrointestinal absorption of iron and 
modified environmental factors (2). Secondary hemochromatosis occurs in patients with 
hereditary anemias including thalassemia and sickle cell anemia (2). α- and β-
thalassemia’s are caused by mutations resulting in defective synthesis of the α- and β-
globulin chains of hemoglobin and are the most common monogenetic diseases in 
humans (2). Secondary iron overload can occur after repeated blood transfusions coupled 
with increased gastrointestinal absorption, which leads to symptoms similar to primary 
iron overload (2). To prevent iron accumulation caused by blood transfusions the use of 
chelation therapy is required at the beginning of the transfusions or phlebotomy (4).      
 
1.2 Cardiac iron overload 
Cardiac iron overload is a common cause of cardiovascular deaths worldwide (5). 
In patients with hemochromatosis or thalassemia major cardiovascular disease 
contributes significantly to their mortality and morbidity (2). Cardiac iron overload has 
been shown to lead to restrictive cardiomyopathy with prominent early diastolic 
dysfunction that progresses to dilated cardiomyopathy characterized by impaired systolic 
function often accompanied by arrhythmias and sudden cardiac death (1-3). Iron overload 
in the heart may also facilitate myocardial ischemia-reperfusion injury because of an 
increased formation of ROS and reduced antioxidant defenses (Figure 1) (2). During the 
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advancement of cardiac iron overload, iron accumulates in the ventricular wall, the 
epicardium, the papillary muscles, and septum (6). Although the exact mechanism of iron 
induced cardiomyocyte dysfunction is not fully understood, recent studies suggest that 
generation of free radicals plays an important role (1-2, 6). 
  
1.3 Iron transport  
The human body uses about 20mg of iron per day for hemoglobin synthesis and 
4-5mg for the production of cellular proteins and approximately 200 billion erythrocytes 
(2). Most of the iron in the body is contained in hemoglobin but it can also be stored in 
hepatocytes and macrophages as ferritin (2, 7). Iron is delivered to most cells through the 
blood as ferric iron bound to serum protein transferrin which is relatively nonreactive (7). 
Movement of iron within the body involves a combination of transporters, including 
transferrin receptors, dimetal transporter 1, ferroportin and a heme receptor (2). 
Ferroportin exports reduced iron into the plasma where it is oxidized and binds to 
transferrin (2). Iron can also be imported as a heme-iron complex into selected tissues (2).  
Recently it has been suggested that L-type Ca2+ channels (LTCC) are responsible 
for the transport of NTBI into the cell (2). Excitable cells and tissues with the greatest 
risk in iron overload have high LTCC activity, which supports the idea that LTCC’s are 
responsible for cellular uptake of NTBI (2). LTCCs are the only Fe2+ transporter whose 
activity increases with elevated iron, which is consistent with NTB1 uptake in the heart 
under iron overload conditions (2). Studies with mice using LTCC blockers, amlodipine 
and verapamil, demonstrated reduced intracellular myocardial iron accumulation and 




There are two treatments available for patients suffering from iron overload, 
phlebotomy and chelation therapy. However, both treatments have been shown to have 
adverse side effects. Phlebotomy is the removal of blood from the body and patients 
receiving phlebotomy can live a normal lifespan if treatment is started early (8). 
Chelators when injected into the bloodstream bind and remove metals from the body (8). 
Chelation therapy has been shown to improve ventricular function, prevent ventricular 
arrhythmias and reduce mortality in patients with secondary iron overload (8). 
Phlebotomy may still result in cardiac iron overload and chelation therapy may cause 
toxic side effects including agranulocytosis, gastric intolerance, and zinc deficiency 
limiting its clinical use (8).      
 
2.0 Oxidative Stress 
 Numerous studies have shown that oxidative stress is involved in the pathogenesis 
of many cardiovascular diseases such as hypertension, type II diabetes, atherosclerosis 
and heart failure (9). Under baseline conditions, ROS are produced in the mitochondria 
during aerobic respiration (10). Vascular cells produce large amounts of ROS including 
superoxide ion (O2•-), hydrogen peroxide (H2O2), the hydroxyl radical and a range of lipid 
radicals (9). O2•- is a primary species involved and can form other ROS as a consequence 
of biochemical reactions (9). The main sources of ROS in cardiovascular tissues are 
NAD(P)H oxidase, xanthine oxidase, uncoupled endothelial nitric oxide synthase and the 






Figure 1: Iron induced cardiac damage. Schematic illustration of iron induced 










2.1 Antioxidant defense system 
 The production of ROS is equalized by enzymatic and non-enzymatic 
antioxidants such as superoxide dismutase (SOD), catalase, glutathione peroxidase 
(GPx), thioredoxins, peroxiredoxins, and ascorbic acid which act as ROS scavengers 
(Figure 2) (12, 13). The contribution of metal ions to ROS generation is most common in 
Fenton or Fenton-type reactions where endogenous metals, such as Fe2+ and Cu+, react 
with hydrogen peroxide to generate hydroxyl radical (13). The cytotoxicity of superoxide 
radical is diminished by SOD that catalyzes the reduction of O2•- to H2O2 and O2 (13). 
Three different isoforms of SOD have been identified in humans and contain copper, zinc 
or manganese ions in their active sites (13). The protective effects of SOD have been 
demonstrated in animal models where SOD significantly protects the heart and brain 
from ischemic injury and prevents alcohol-induced liver injury (13). Antioxidant 
enzymes such as catalase and GPx scavenge H2O2 by reducing it to H2O (13). Catalase is 
located in the peroxisome and its function is to promote the conversion of H2O2 to water 
and molecular oxygen (14). GPx enzymes in the presence of tripeptide glutathione (GSH) 
will add two electrons to convert peroxides to water while oxidizing GSH (Figure 2) (14). 
These antioxidant enzymes eliminate peroxides as potential substrates for the Fenton 
reaction (14). The reduction of H2O2 by metal ions generates the hydroxyl radical, which 
is considered to be the most reactive ROS (13). The Fenton reaction occurs when iron 
reacts with endogenous H2O2 to generate OH- and OH• (13). Copper generates hydroxyl 





Figure 2: Antioxidants and free radicals. Redox reactions illustrating the production of 
some ROS and the antioxidants involved in scavenging the free radicals. Image modified 
from Flora (2009) (14).  
 
2.2 Oxidative stress mediated cell damage  
2.2.1 Apoptosis 
 Apoptosis is a form of programmed cell death (10, 11). Apoptosis is an early 
event in both inflammatory-mediated and mechanical injury (11). Release of cytokines 
such as TNF-α (tumor necrosis factor) after sepsis, ischemia-reperfusion, or shock 
contributes to endothelial apoptosis (10, 11). ROS has been shown to initiate apoptosis 
(10, 11). DNA damage is prominent in the presence of excess ROS, with mitochondrial 
DNA (mtDNA) being highly susceptible to ROS-mediated damage, due to its close 
proximity with the major source of ROS within the cell (10). Oxidative stress can cause 
DNA damage by binding to DNA forming adducts or by causing single or double-
stranded breaks in nuclear DNA (10). ROS also causes protein damage which occurs via 
formation of protein carbonyls in several cellular proteins in their amino acids, lysine, 
arginine, proline and threonine (10). Bax/Bak is a pro-apoptotic protein of the Bcl-2 
family that are negatively regulated by Bcl-2 (22). Oligomerization of Bax/Bak proteins 
8 
 
is believed to form ion conductance channels which alter the permeability of the 
mitochondrial membrane (16). Loss of membrane integrity promotes the release of pro-
apoptotic factors located between the matrix and inner membrane space (16). ROS also 
modulates several lipoproteins, such as LDL, and causes lipid peroxidation (10). Damage 
to extracellular lipids is demonstrated by the accumulation of oxidized LDL, leading to 
the formation of foam cells from macrophages which contribute to the progression of 
atherosclerosis (10). Oxidation of cellular membrane systems results in altered fluidity 
and membrane damage (10).  Cardiac iron overload has been shown to cause apoptosis 
resulting in loss of cardiomyocytes (2). Amplified apoptosis and/or necrosis may be due 
to mitochondrial dysfunction caused by iron induced oxidative stress (2).   
 
2.2.2 Necrosis 
 Necrosis is a form of programmed cell death that is associated with oxidative 
stress, and triggers distinct changes in cell morphology distinguishing it from apoptosis 
(16). Permeability changes in the inner mitochondrial membrane, typically from the 
presence of ROS, resulting in the formation and opening of the mitochondrial 
permeability transition pore (mPTP) is a primary characteristic of necrosis (16). Studies 
suggest that the mPTP opening of the mitochondrial pore may activate apoptosis when 
ATP levels are maintained but a severe decline in ATP triggers necrotic cell death from a 
loss of electrochemical gradient across the inner mitochondrial membrane (16). 
Consequential swelling of the inner mitochondrial membrane leads to the rupturing of the 
outer mitochondrial membrane, releasing mitochondrial proteases into the cytoplasm 
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(16). The release of enzymes and proteins induces an inflammatory response by nearby 
cells which is another distinct feature of necrosis (16).      
 
2.2.3 Autophagy 
 Oxidative stress has been shown to stimulate autophagy during periods of nutrient 
deprivation, ischemia/reperfusion and hypoxia (10). Under physiological conditions, 
autophagy is a constant, cytoprotective pathway used by eukaryote cells to degrade and 
recycle cellular components, including aged proteins and damaged organelles (20, 21). 
Recent evidence has shown that under baseline conditions autophagy is an important 
homeostatic mechanism for maintaining normal cardiovascular function (21). 
Enhancement of autophagy has been observed in developing mouse embryos, suggesting 
that autophagy plays an important role in cell development and differentiation (17). 
Autophagy is also up-regulated during periods of cellular starvation as a means to 
generate the nutrients to sustain cell survival (17-19). Therefore, autophagy is thought to 
be involved in many physiological processes, including cellular differentiation, tissue 
remodelling, and modulating growth (21, 22). Autophagic degradation and removal of 
damaged oxidized proteins in response to oxidative stress has been shown to benefit the 
cell (17). Conversely, excessive induction of autophagy by severe oxidative stress may 
activate signaling pathways that have a role in cardiomyopathy (17, 20, 21). During 
ischemia, the resulting decrease in ATP generation results in the phosphorylation of 
AMP-activated protein kinase (AMPK), which results in autophagosome formation 
through inhibition of the mammalian target of rapamycin (mTOR) (17). Ischemic insult 
also results in phosphorylation of heat shock protein (Hsp)20 at serine residue 16, leading 
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to cardioprotection by enhancing autophagy (17). During reperfusion, ROS enhances 
autophagy by damaging organelles, cytosolic proteins and causes lipid peroxidation in the 
mitochondria (17). Antioxidants such as catalase and SOD are targeted by 
autophagosomes, thereby increasing the presence of ROS and creating a positive 
feedback loop which leads to cell death (17). AMPK activity is also decreased during 
reperfusion, thus increasing autophagic death and beclin-1 upregulation (17).       
 
3.0 AMPK Signaling 
 AMPK is a sensor of cellular energy status and plays an important role in 
modulating energy metabolism and ROS regulation (23-25). Due to its homeostatic 
activity, AMPK is being considered as a possible therapeutic target for many 
pathophysiological conditions including diabetes, obesity, and cardiomyopathy (23-24). 
These diseases are associated with chronic ROS accumulation which links to an 
insensitivity of AMPK activation (23). AMPK is known to be activated during stress 
conditions such as starvation, hypoxia, and ischemia (26). Upon energy exhaustion, 
AMPK stimulates ATP-production pathways while inhibiting ATP-consuming pathways, 
thereby regulating metabolic processes towards cellular energy homeostasis (26). 
Glucose deprivation in cardiomyocytes induces autophagy via activation of AMPK (26). 
Glucose deprivation has been shown to increase AMPK phosphorylation and decrease 
mTOR phosphorylation (28). The mTOR-dependent signaling pathway, which 
phosphorylates and inhibits the ULK1 kinase complex, regulates the induction of 
autophagy through AMPK (23, 28). Compromised cellular energy production inhibits 
mTOR through activation of AMPK and consequently, phosphorylation of the tuberous 
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sclerosis complex (TSC) (25, 28). TSC2 inhibits mTORC1 leading to a decrease in 
protein synthesis and cell growth (27). mTOR can also be inhibited directly by AMPK by 
directly phosphorylating the rotor compartment of mTOR (Figure 3) (27). Since mTOR 
negatively regulates autophagy, this pathway may be important in regulating cell death in 
pathological conditions (25). In cardiac muscle, insulin antagonizes the activation of 
AMPK and this appears to involve activation of the protein kinase B (Akt) (Figure 3) 
(28). Phosphorylation of AMPK at residues Ser485 and Ser491 by Akt provokes AMPK 
activation via phosphorylation at Thr173 by LKB1 kinase (28). mTOR was shown to be 
associated with the mitochondrial outer membrane, thereby sensing changes in the ratio 
between ATP/AMP controlling autophagy (28). mTOR also regulates the ubiqiotination, 
internalization and turnover of specific nutrient transporters (31). mTORC1 can regulate 
the trafficking of nutrient transporters and promote the uptake of various nutrients 
including glucose, amino acids and iron (31). Akt is a major effector of receptor tyrosine 
kinases, which modulate cell growth, apoptosis, protein synthesis and energy metabolism 
(30).  
 AMPK also regulates p53 expression and phosphorylation (29). During stress 
conditions, the p53 pathway suppresses the AKT and mTOR pathways and promotes the 
induction of apoptosis (29, 31). AMPK activity is increased during stress signals and 
negatively regulates the IGF-I-Akt-mTOR pathways in a p53-dependent fashion (29). 
p53 has been shown to regulate autophagy directly through its transcription regulation of 
damage-regulated autophagy modulator, which is a lysosomal protein (31). Akt inhibits 
apoptosis through inactivation of the proapoptotic factors BAD and procaspase-9 (30). 
Akt also phosphorylates and inhibits the TSC1/TSC2 protein complex, leading to 
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activation of mTOR which in turn upregulates cell growth and protein synthesis (30). 
Translocation of Akt from the plasma membrane to the nucleus results in the 
phosphorylation of FOXO transcription factors (31). FOXO proteins then exit the nucleus 
resulting in a transcriptional program that enhances oxidative phosphorylation for 
efficient energy production, increasing production of antioxidants, and heat shock 
proteins (31). Therefore, removal of FOXO from the nucleus by the translocation of Akt 








Figure 3: Akt/mTOR signaling pathway. Schematic illustration of apoptosis and 
prosurvival signaling pathways. Image modified from Carnero et al (2008) (52). AMPK 
5’AMP-activated protein kinase, Akt protein kinase B, mTOR mammalian target of 
rapamycin, FOXO1 forkhead box O1, BAX BCL2 associated X protein, BCL B-cell 







4.0 STAT3 signaling 
Signal transducer and activator of transcription 3 (STAT3) protein is involved in 
cardiomyocyte protection and hypertrophy (37). STAT3 is involved in a broad range of 
cellular and molecular pathways that direct remodeling processes in cardiac physiology 
and pathophysiology (37). It can act as a signaling molecule, transcription factor and has 
recently been identified as a mitochondrial protein involved in energy production (37). 
Cytokines of the interleukin-6 family are activated via their common receptor gp130, that 
subsequently forms homo- or heterodimers, STAT3 then translocates to the nucleus 
where it activates the transcription of downstream target genes by binding to specific 
DNA elements in their promoter regions (37). Activation of STAT3 by the gp130 
receptor system involves the constitutive assembly of JAK and tyrosine and their 
catalytic activation, leading to a phosphorylation of C-terminal tyrosine residues in the 
intracellular domain of the gp130 receptor (37). After detachment from the receptor, 
phosphorylation of STAT permits the homo- or heterodimerization of STAT proteins and 
their importation into the nucleus where it immediately activates its target genes (37). 
STAT3 has been shown to repress the expression of p53 and thereby down regulates pro-
apoptotic genes including Bax, caspase 6, and FAS (37). In the heart, cardioprotective 
effects of STAT3 have been linked to a direct transcriptional up-regulation of antioxidant 
enzymes such as MnSOD, as well as the induction of anti-apoptotic Bcl-xL and Hsp70 
(37). Therefore, STAT3 seems to contribute to the antioxidant defense mechanisms and 
additional cytoprotective pathways, thereby playing an important role in cardiomyocyte 
survival.  
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5.0 Secoisolariciresinol diglucoside 
 Secoisolariciresinol diglucoside (SDG) is a phytochemical antioxidant present in 
flaxseeds (32). SDG is converted to mammalian lignans after ingestion and further 
undergoes hydrolysis to secoisolariciresinol (SECO) (34). SECO is then converted to 
enterodiol (ED) and enterolactone (EL) which have a similar structure to oestradiol, the 
active form of oestrogen (Figure 4) (34). Their structural similarities allow ED and EL to 
bind to oestrogen receptors and exert weak oestrogenic effects including the induction of 
phase 2 proteins (oxidant scavengers) and inhibition of enzymes such as 5α-reductase and 
aromatase which may result in protection against chronic diseases (34). SDG has been 
shown to reduce the production of inflammatory mediators and oxidative stress markers 
in rabbits fed a high cholesterol diet and in an in vitro cardiac iron overload condition 
(32-33). SDG treatment was also found to reduce the development of atherosclerosis and 
diabetes in rats (32). Prasad (1997) demonstrated that SDG has an ability to scavenge OH 




Figure 4: Structure of SDG metabolites. Demonstrates the conversion of SDG to it’s 











 The purpose of this study was to explore SDG’s role in the AMPK signaling 
pathway and to also investigate its effect on antioxidant protein expression, MnSOD and 
catalase, in a cardiac iron overload condition. Another objective of this study was to 
determine if SDG pretreatment would attenuate cell death and damaged mitochondria 
during iron induced oxidative stress. 
7.0 Hypothesis 
 In this study we hypothesize that SDG will increase the activity of the pro-
survival proteins AMPK, mTOR, Akt, while maintaining endogenous antioxidants 
catalase and MnSOD. SDG will also reduce the amount of necrotic cells caused by 















Rat ventricle cardiac cells, H9c2 cells (American Type Culture Collection, 
Manassas, VA), were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-
Aldrich, St. Louis, MO) supplemented with 10% (vol/vol) fetal bovine serum (Hyclone, 
Pittsburgh, PA) and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA) in a 
humidified atmosphere containing 5% CO2 at 37°C. Cells were grown to 80% confluency 
before treatments. All experiments were conducted in the absence of serum and 
antibiotics.     
Ammonium iron (III) citrate preparation 
Iron solution was prepared by dissolving ammonium iron (III) citrate (Sigma-
Aldrich, St. Louis, MO) into serum- and antibiotic-free DMEM. H9c2 cells were treated 
with an iron concentration of 50 μM. This concentration was based on previous published 
work (Puukila, 2015) (33). Treated cells were incubated for 6 hours, 12 hours, or 24 
hours at 37°C. Cell death was assessed after 6 hours of iron treatment, pro-survival 
protein levels and oxidative stress markers were analysed after 6 and/or 12 hours of iron 
treatment, and antioxidant levels were assessed after 24 hours. Shorter incubation times 
were used to determine the effect of acute iron overload on cell signaling proteins.   
Secoisolariciresinol diglucoside preparation  
SDG (250 or 500 μM) was prepared by dissolving SDG into serum- and 
antibiotic-free DMEM. H9c2 cells were incubated with SDG for 24 hours prior to iron 




Necrotic cells were assessed by using Propidium Iodide (PI) stain. After iron 
treatment, cells were removed from the flasks and centrifuged at 500×g for 5 minutes at 
room temperature. The supernatant was removed, and cells were washed twice with 1X 
wash buffer (Sigma-Aldrich, Oakville, ON, Canada). Finally, the cell pellet was 
resuspended in 400 μL of 1X wash buffer, followed by the addition of 8 μL of PI solution 
(250 μg m-1). The percentage of PI positive cells was determined by using flow cytometry 
(BDFACS Calibur flow cytometer).   
Mitochondrial membrane potential assay 
Mitochondrial membrane potential was measured using the JC-10 assay kit 
(Sigma-Aldrich; Oakville, ON). A suspension of H9c2 cells (5.0×105 cells/well; 3 mL) 
was seeded onto a 6 well plate and was allowed to adhere overnight. After 24 hours, cells 
were treated for 6 hours with 50 μM iron solution or serum- and antibiotic-free DMEM. 
Media was then aspirated and cells were scraped into 500 μL solution containing 5 μL of 
JC-10 dye per millilitre of assay buffer. Cells were then incubated in the dark for 15 
minutes at 37°C. Cells were treated with 30μM FCCP (carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone) for 30 minutes prior to the JC-10 solution. FCCP 
depolarises the membrane by transporting protons across the inner mitochondrial 
membrane and can be used as a positive control for this assay. In apoptotic and necrotic 
cells, the JC-10 dye forms green fluorescent aggregates in the damaged mitochondria. 
Aggregates were measured using flow cytometry on channels FL1 and FL2 (Becton 




H9c2 cells were disrupted and homogenized in 200 μL of Pathscan buffer (25 mM 
Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, and 2 mL Triton X made up to 200 mL with 
distilled water) containing protease inhibitor cocktail (Sigma-Aldrich; Oakville, ON), 
sodium fluoride and sodium orthovanadate using the Tissuelyser (Qiagen, Redwood City, 
CA, USA) at 30 Hz for 3 minutes. Cell debris was removed by centrifugation at 8,000xg 
for 10 minutes at 4°C. Protein content was determined using the DC protein assay 
following manufacturer’s protocol (Bio-Rad Laboratories, Inc., Hercules, CA, USA). For 
each sample, 30 μg of protein was boiled at 95°C for 5 minutes in loading buffer and 
subjected to SDS-page electrophoresis. Proteins were transferred to a nitrocellulose 
membrane using a Trans-blot apparatus (Bio-Rad, Mississauga, ON, Canada). The 
membrane was blocked with 5% BSA for active proteins or 5% milk for non-active 
proteins for 1 hour at room temperature. The membrane was then incubated with the 
appropriate antibody overnight at 4°C. Following washing in 1X Tween-Tris buffered 
saline (TBST; pH 7.4), the membrane was incubated with the appropriate horseradish 
peroxidase (HRP)- conjugated secondary antibody for 1 hour at room temperature. 
Finally, the membrane was washed in 1X TBST, and protein expression was visualized 
using enhanced chemiluminescence reagent. Following chemiluminescent imaging, 
membranes were stripped and re-blotted accordingly. All antibodies were purchased from 
Cell Signaling Technologies (Danvers, MA, USA) except for anti-4-Hydroxynonenal 
(4HNE) which was purchased from Abcam (Abcam; Cambridge, MA), β-actin was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and catalase from 
Sigma (Sigma-Aldrich; Oakville, ON). The dilutions of the antibodies were as follows: 
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anti-AMPK (1:1000), anti-pAMPK (1:500), anti-Akt (1:1000), anti-pAkt (1:250), anti-
mTOR (1:1000), anti-pmTOR (1:500), anti-STAT3 (1:1000), anti-pSTAT3 (1:1000), 
anti-catalase (1:1000), anti-mnSOD (1:1000), anti-4HNE (1:1000), and β-actin (1:5000). 
Anti-rabbit IgG (1:1000; Cell Signaling Technologies) secondary antibody was used for 
all primary antibodies except for mTOR, catalase, and β-actin which used anti-mouse IgG 
(1:1000, 1:5000 and 1:5000, respectively; Cell Signaling Technologies).    
Statistical analysis 
Data are presented as the mean ± standard error of the mean (SEM). Data was 
analyzed using the one-way analysis of variance (ANOVA) followed by Tukey’s post-
hoc test for multiple comparisons (GraphPad Prism 6 software; San Diego, CA). 
















Effect of SDG on iron-induced necrosis in H9c2 cardiomyocytes 
Iron-induced necrosis was investigated in cultured H9c2 cells by using a 
propidium iodine (PI) stain and mean fluorescence was measured using flow cytometry. 
Six hours of 50 μM iron treatment caused a significant increase (81.8%) in necrotic cells 
compared to the untreated control condition as shown in Figure 5-A as a shift in 
fluorescence intensity. Necrotic cells were reduced (24.3%) after 24-hour pre-treatment 
with 500 μM SDG, as indicated by increased mean FL1 fluorescence versus the iron 





Figure 5: Effect of iron and SDG on necrosis. Depicts PI staining of necrotic cells in 
control, 50 μM iron (Fe) treated, 500 μM secoisolariciresinol diglucoside (SDG) treated 
and SDG + Fe treated H9c2 cells. Cells were treated with SDG for 24 hours followed by 
6 hours of Fe treatment. Mean fluorescence intensity was measured using flow 






Effect of iron and SDG on mitochondrial membrane potential 
Changes in the mitochondrial membrane potential were measured using the JC-10 
assay. JC-10 dye accumulates in the mitochondria of healthy cells forming fluorescent 
red aggregates, however in apoptotic and necrotic cells JC-10 dye will remain in 
monomeric form fluorescing green. The ratio between green (lower right quadrant) to red 
(upper right quadrant) determines change in mitochondrial membrane potential (Figure 6-
A). Fluorescence was measured using flow cytometry. After 6 hours of iron treatment, 
there was a decrease (55.6%) in mitochondrial membrane potential compared to the 
control but this difference was not statistically significant. However, 24-hour pre-
treatment of SDG prior to iron treatment caused a statistically significant decrease 














Figure 6: Effect of iron and SDG on the mitochondrial membrane potential. 
Mitochondrial membrane potential was measured using the JC-10 assay. Mean 
fluorescence intensity was measured using flow cytometry (A). A ratio between healthy 
and apoptotic cells was calculated for control, 50 μM iron (Fe) treated, 500 μM 
secoisolariciresinol diglucoside (SDG) treated and SDG + Fe treated groups (B). Data 




Effect of iron and SDG on 4HNE 
 Immunoblotting was used to investigate the effect of iron and SDG on the 
oxidative stress marker, 4HNE. 4HNE can result in multiple bands on a Western blot 
depending how it is cleaved by proteases after being released from the membrane. All 
protein bands present on the membrane were used to measure 4HNE protein content. 
4HNE was significantly increased after 6 hours of iron treatment and was also increased 
in the SDG treated cells compared to control. SDG treatment prior to iron treatment 















Figure 7: Effect of iron and SDG on 4HNE protein expression. Protein expression of 
4HNE in control, 50 μM iron (Fe) treated, 250 µM secoisolariciresinol diglucoside 
(SDG) treated and SDG + Fe treated H9c2 cells. Cells were treated with SDG for 24 
hours and Fe for 6 hours. Protein expression was determined using Western blot and data 




Effect of iron and SDG on MnSOD and catalase protein expression 
To investigate the effect of iron and SDG on antioxidant protein expression, 
MnSOD and catalase, immunoblotting was performed. After 24 hours of iron treatment 
there was no significant difference in the amount of MnSOD or catalase compared to 
control (Figure 8-A, B). However, in cells treated with both SDG and iron, there was a 
significant increase in the amount of catalase compared to control and iron overload 





Figure 8: Effect of iron and SDG on antioxidant protein expression. Protein 
expression of MnSOD (A), and catalase (B) in control, 50 μM iron (Fe) treated, 250 µM 
secoisolariciresinol diglucoside (SDG) treated and SDG + Fe treated H9c2 cells. Cells 
were treated with SDG for 24 hours and Fe for 24 hours. Protein expression was 
determined using Western blot and data is expressed as a ratio to β-actin (*/# = p ≤ 0.05 





Effect of iron and SDG on Akt activity 
To further investigate the effect of iron and SDG on intrinsic pro-survival 
signaling pathways, the activity of Akt was measured using immunoblotting. To 
determine the amount of active protein in each treatment, a ratio is measured between the 
active and non-active forms of Akt. After 6 hours of iron treatment, Akt activity was 
significantly decreased in SDG treated and the combination treatment (Figure 9). Iron 




Figure 9: Effect of iron and SDG on Akt activity. Akt activity after 6 hours of iron (Fe) 
treatment in control, 50 μM Fe treated, 250 µM secoisolariciresinol diglucoside (SDG) 
treated and SDG + Fe treated H9c2 cells. Protein was determined using Western blot and 







Effect of iron and SDG on AMPK activity  
AMPK activity was measured using immunoblotting. After 6 hours of iron 
treatment there was no significant difference noted between any of the conditions (Figure 
10-A). However, after 12 hours of iron treatment AMPK activity was increased in the 
combination treatment but this difference was not found to be significant compared to 
control and iron overload condition (Figure 10-B). There was an increase between the 12 





Figure 10: Effect of iron and SDG on AMPK activity. AMPK activity after 6 hours of 
iron (Fe) treatment (A) and AMPK activity after 12 hours of Fe treatment (B). AMPK 
activity was shown in control, 50 μM Fe treated, 250 µM secoisolariciresinol diglucoside 
(SDG) treated and SDG + Fe treated H9c2 cells. Protein was determined using Western 





Effect of iron and SDG on mTOR activity 
Immunoblotting was used to determine the activity of the protein mTOR. After 6 
hours of iron treatment there was no significant difference between conditions (Figure 





Figure 11: Effect of iron and SDG on mTOR activity. mTOR activity after 6 hours of 
iron (Fe) treatment (A) and mTOR activity after 12 hours of Fe treatment (B). mTOR 
activity was shown in control, 50 μM Fe treated, 250 µM secoisolariciresinol diglucoside 
(SDG) treated and SDG + Fe treated H9c2 cells. Protein was determined using Western 




Effect of iron and SDG on STAT3 
The activity of the transcription factor STAT3 was measured using Western blot 
technique. After 12 hours of iron treatment, STAT3 activity was significantly reduced in 
comparison to the control. Pre-treatment with SDG increased STAT3 activity but the 





Figure 12: Effect of iron and SDG on STAT3 activity. STAT3 activity after 12 hours 
of iron (Fe) treatment was assessed via Western blot. STAT3 activity was measured in 
control, 50 μM Fe treated, 250 µM secoisolariciresinol diglucoside (SDG) treated and 
SDG + Fe treated H9c2 cells. Data was reported as a ratio of phosphorylated protein to 









Iron overload cardiomyopathy is responsible for substantial cardiovascular 
morbidity and mortality (1, 2). Oudit et al (2006), demonstrated that free iron in the 
plasma enters cardiomyocytes via L-type Ca2+ channels as reduced iron (2). Fe2+ can then 
lead to the formation of ROS via the Fenton reaction by interacting with ROS produced 
in the electron transport chain in the mitochondria, interconverting between Fe2+ and Fe3+ 
to further generate ROS (Figure 2). Currently the only treatment options for iron overload 
are phlebotomy or chelation therapy, where both treatments can cause adverse effects. 
SDG is an antioxidant present in flaxseed and has been shown to decrease the production 
of inflammatory mediators and ROS. A recent study demonstrated that SDG abrogated 
the iron-induced increase in oxidative stress, inflammation, and apoptosis (33). For this 
study, we investigated the effects of iron overload on cell necrosis, antioxidant status, and 
AMPK signaling in H9c2 cardiac cells. A range of time points were used for iron 
exposure to determine which proteins in this signaling pathway are activated by short (6 
hour) or long (12 or 24 hour) iron exposure. Since cellular protection by SDG is dose 
dependent, two concentrations of SDG were used (250 μM and 500 μM).     
 Iron overload in H9c2 cells resulted in an increase in necrosis as measured via 
flow cytometry. Necrosis is a form of cell death characterized by the permeability 
changes in the inner mitochondrial membrane resulting in the rupture of the outer 
mitochondrial membrane releasing proteases into the cytosol (16). PI is a non-membrane 
permeable dye that can enter into damaged cells and bind to their DNA. In our study, PI 
positive cells were increased after 6 hours of 50 μM iron treatment and were rescued by 
500 μM pretreatment of SDG (Figure 5). This result suggests that iron overload increases 
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necrosis in H9c2 cells and SDG can reduce the amount of necrotic cells most likely due 
to its oxidant scavenging properties.  
 Iron-mediated damage likely involves the role of mitochondrially generated ROS. 
Previous studies demonstrated that iron overload causes progressive loss of intact 
mtDNA, decreased expression of respiratory chain subunits encoded by mitochondrial, 
but not nuclear, DNA, and diminished respiratory function (38, 40, 44, 46). They also 
reported that iron-mediated cytotoxicity involves ROS generated by the mitochondrion 
itself because cells lacking mtDNA are remarkably tolerant of iron overload (38). Chan et 
al (2015) also demonstrated that iron overload decreased the mitochondrial membrane 
potential (44). JC-10 dye will accumulate in the mitochondrial matrix where it forms red 
fluorescent aggregates in healthy cells, but in apoptotic and necrotic cells, JC-10 exists in 
monomeric form and fluoresces green. In our study, iron treated cells had no difference in 
the ratio of JC-aggregates to monomers between the control group after 6 hours of iron 
treatment, but showed an increase in the ratio of JC-aggregates to monomers in the SDG 
+ iron treated group compared to the control group (Figure 6). We would expect to see an 
increase in green monomers in the iron treated group since the mitochondria are a main 
target for iron induced oxidative stress damage. This result may be because acute iron 
exposure may not be sufficient to cause mitochondrial damage or the concentration of 
iron may be too low to elicit a response. Further studies are required to determine the 
effect of chronic iron overload on the mitochondrial membrane potential.  
 Overproduction of ROS causes oxidative damage in the cell including lipid 
peroxidation (15). Lipid peroxidation is the process of free radicals stealing electrons 
from lipids in cell membranes and the most stable bioactive lipid peroxidation product is 
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4HNE (15). Previous studies have demonstrated that 4HNE caused an increase in cell 
death and proteasome activity in H9c2 cardiac cells (49-50). After iron treatment, 4HNE 
was significantly increased compared to the control and pretreatment of the cardiac cells 
while SDG attenuated the iron-induced increase in this oxidative stress marker (Figure 7). 
However, 4HNE concentration was also increased in the SDG condition, suggesting high 
concentrations of this compound under physiological conditions may negatively regulate 
oxidative stress. These data suggest SDG has the ability to reduce oxidative stress in iron 
overload condition.  
Antioxidants scavenge ROS to achieve cellular redox balance. We investigated 
the protein content of MnSOD, which is an antioxidant that catalyzes the reduction of 
O2•- to H2O2 and O2, and catalase, which promotes the conversion of H2O2 to H2O and 
O2. Bartfay et al (1999) reported that iron overload decreased antioxidant defenses and 
increased ROS in a murine model (39, 51). Previous work in our lab demonstrated SOD 
activity was significantly increased in the SDG + iron combination condition and SDG 
alone treatment compared to iron and control treatments (33). In our study, iron treatment 
increased the SOD protein expression as well as in the SDG treatment but the SDG + iron 
treated cardiac cells reduced SOD to control levels (Figure 8-A). Discrepancies between 
previous study may be due to different concentrations of SDG treatment. Catalase was 
significantly increased when cells were treated with both SDG and iron (Figure 8-B). 
This data suggests that SDG can boost intrinsic antioxidant activity in iron overload 
condition.   
 The Akt/mTOR pathway is a pro-survival pathway that is involved in many 
cellular processes including autophagy, cell growth, and transcription of cellular 
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metabolites such as antioxidants (41-42). Wang et al, 2011, showed chronic iron overload 
in a gerbil model reduced the activity of Akt (41). In our study, after acute iron exposure, 
there was no difference between the iron and control condition, but SDG significantly 
reduced the activity of Akt compared to the iron and control cells (Figure 10). Dikshit et 
al (2016), demonstrated SDG reduced the expression of Akt in hens. These data suggest 
SDG has an effect on Akt protein and gene expression (43).   
AMPK, a downstream target of Akt, reserves cellular energy status and serves as 
a key regulator of cell survival in response to energy stress. No significant difference was 
found in AMPK activity after 6 or 12 hours of iron treatment. However, Puukila et al 
(2015) showed a decrease in AMPK expression after 24 hours of iron treatment. This 
suggests a chronic iron exposure may affect AMPK activity (33). SDG pretreatment 
increased the activity of AMPK after iron overload suggesting AMPK may be targeted by 
SDG to provide protection against iron-induced oxidative stress. mTOR is a downstream 
target of AMPK and regulates a number of cellular processes including autophagy and 
cell growth. mTOR activity was not affected by iron or SDG suggesting that after acute 
iron exposure mTOR is not altered by SDG and iron (Figure 11). Further experiments 
need to be conducted to determine if the Akt-mTOR pathway is a key player in protection 
against iron overload and if the activity of Akt is related to the production of catalase 
after SDG exposure.   
The STAT3 transcription factor has been shown to have an impact on 
cardiomyocyte survival by regulating genes involved in anti-oxidative pathways, 
modulation of hypertrophic growth, angiogenesis, and metabolic reserves (37, 47-48). 
STAT3 has been shown to up-regulate MnSOD in mice thereby suppressing ROS 
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accumulation (37, 45). After iron treatment, STAT3 activity was significantly reduced 
compared to the control cells (Figure 12). Pre-treatment with SDG increased the activity 
of STAT3, but this was not significantly different from the control cells. This increase 
may result in the activation of antioxidant proteins, such as catalase whose expression 
was increased due to SDG treatment.  
Using H9c2 cardiac cells exposed to iron overload condition, we demonstrated an 
increase in cell death, antioxidants, and decrease in STAT3. This was observed by 
measuring cell death, antioxidant protein expression, and cell survival proteins. SDG 
abrogated the increase in cellular damage and the reduction of prosurvival proteins, 
further confirming the cardioprotective role for SDG in cardiac iron overload. However, 
further experiments are required to determine the effect of this condition on Akt/mTOR 
signaling.    
Limitations  
This study was limited by using an in vitro model instead of an in vivo model of 
cardiac iron overload and as such the results should be extrapolated accordingly. Markers 
of cell survival and oxidative stress were studied by only measuring protein expression, 
further enzyme activity assays and gene expression analysis should be performed to gain 






 Cardiac iron overload directly correlates with cardiac dysfunction and may 
ultimately cause heart failure. Cardiac dysfunction is likely caused by a combination of 
oxidative stress and inflammation, which can lead to cell death. SDG is an antioxidant 
phytoestrogen present in flax seeds that has been shown to prevent the development of 
hypercholesterolemic atherosclerosis and diabetes. Here we investigated the role of SDG 
on markers of cell death, mitochondrial dysfunction, and pro-survival signaling. The 
results of these in vitro studies demonstrated that H9c2 rat cardiac cell were susceptible 
to iron overload, as demonstrated by increased necrosis and mitochondrial damage. Pre-
treatment with SDG abrogated the detrimental effects of iron overload, suggesting a 
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